BACKGROUND: Atypical antipsychotics decrease irritability in autism. They also affect the cytokine network. Psychological stress, depression, and, possibly, autism spectrum disorder (ASD) are associated with the production of pro-inflammatory cytokines. We sought to determine if risperidone treatment led to changes in plasma cytokine levels. METHODS: Forty-five subjects from an open-label study of risperidone treatment of children and adolescents with ASD, ages 4-18 years, had an analysis of 27 different cytokines at baseline and after 8 weeks of treatment using multiplex assays (Millipore) and read on the Luminex 100(™) platform. We examined changes in each of the cytokine levels in the entire group, and also compared changes in cytokines in responders versus nonresponders. RESULTS: After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (MCP-1) (p=0.0024). Six of the 48 subjects met two criteria for responders to risperidone, and the median values of interleukin (IL)-5 were significantly higher (p=0.005) in the overall responder group than in nonresponders. CONCLUSIONS: Two cytokines, eotaxin and MCP-1, which have previously been identified as abnormally elevated in children with autism, decreased during treatment with risperidone. This suggests a possible mechanism of action of risperidone treatment and a balancing of the immune system in affected subjects in this very preliminary study.
BACKGROUND: Atypical antipsychotics decrease irritability in autism. They also affect the cytokine network. Psychological stress, depression, and, possibly, autism spectrum disorder (ASD) are associated with the production of pro-inflammatory cytokines. We sought to determine if risperidone treatment led to changes in plasma cytokine levels. METHODS: Forty-five subjects from an open-label study of risperidone treatment of children and adolescents with ASD, ages 4-18 years, had an analysis of 27 different cytokines at baseline and after 8 weeks of treatment using multiplex assays (Millipore) and read on the Luminex 100(™) platform. We examined changes in each of the cytokine levels in the entire group, and also compared changes in cytokines in responders versus nonresponders. RESULTS: After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (MCP-1) (p=0.0024). Six of the 48 subjects met two criteria for responders to risperidone, and the median values of interleukin (IL)-5 were significantly higher (p=0.005) in the overall responder group than in nonresponders. CONCLUSIONS: Two cytokines, eotaxin and MCP-1, which have previously been identified as abnormally elevated in children with autism, decreased during treatment with risperidone. This suggests a possible mechanism of action of risperidone treatment and a balancing of the immune system in affected subjects in this very preliminary study.
Authors: Zuzana Tobiasova; Klaas H B van der Lingen; Lawrence Scahill; James F Leckman; Yan Zhang; Wookjin Chae; James T McCracken; Christopher J McDougle; Benedetto Vitiello; Elaine Tierney; Michael G Aman; L Eugene Arnold; Liliya Katsovich; Pieter J Hoekstra; Fred Volkmar; Alfred L M Bothwell; Ivana Kawikova Journal: J Child Adolesc Psychopharmacol Date: 2011-11-09 Impact factor: 2.576
Authors: Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac N Pessah; Judy Van de Water Journal: J Neuroimmunol Date: 2010-11-20 Impact factor: 3.478
Authors: Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac N Pessah; Judy Van de Water Journal: Brain Behav Immun Date: 2010-09-15 Impact factor: 7.217
Authors: Sheikh F Ahmad; Mushtaq A Ansari; Ahmed Nadeem; Saleh A Bakheet; Laila Y Al-Ayadhi; Sabry M Attia Journal: Psychopharmacology (Berl) Date: 2018-11-19 Impact factor: 4.530
Authors: Paul Whiteley; Ben Marlow; Ritika R Kapoor; Natasa Blagojevic-Stokic; Regina Sala Journal: Front Psychiatry Date: 2021-12-17 Impact factor: 4.157
Authors: Maria Fiorentino; Anna Sapone; Stefania Senger; Stephanie S Camhi; Sarah M Kadzielski; Timothy M Buie; Deanna L Kelly; Nicola Cascella; Alessio Fasano Journal: Mol Autism Date: 2016-11-29 Impact factor: 7.509
Authors: Maria de Los Angeles Robinson-Agramonte; Elena Noris García; Jarasca Fraga Guerra; Yamilé Vega Hurtado; Nicola Antonucci; Neomar Semprún-Hernández; Stephen Schultz; Dario Siniscalco Journal: Int J Mol Sci Date: 2022-03-11 Impact factor: 5.923